Darzalex can now be used in combination with two standard of care regimens —lenalidomide and dexamethasone, or bortezomib and dexamethasone — for the treatment of patients with multiple myeloma who have received at least one prior therapy, according to a company news release.
The FDA first approved the drug in November 2015 and the medication earned breakthrough therapy designation for the new indication in July 2016.
More articles on supply chain:
Novo Nordisk, Sanofi to battle for sales with new combination diabetes drugs: 4 takeaways
Sanofi earns FDA approval for type 2 diabetes treatment
FDA approves Novo Nordisk’s new combination therapy for type 2 diabetes
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.